Soluble CD163: A biomarker linking macrophages and insulin resistance

Diabetologia

Volumn 55, Issue 6, 2012, Pages 1856-1862

  Parkner, T ^a   Sorensen L P ^a   Nielsen, A R ^a   Fischer, C P ^b   Bibby, B M ^c   Nielsen, S ^a,b   Pedersen, B K ^b   Moller H J ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c AARHUS UNIVERSITY   (Denmark)

Author keywords

Biomarker; CD163; Diabetes; HOMA IR; Insulin resistance; Macrophages; Metabolic syndrome; Soluble CD163; Type 2 diabetes

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CD163 ANTIGEN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INTERLEUKIN 6; SOLUBLE CD163 ANTIGEN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CELL SURFACE RECEPTOR; DIFFERENTIATION ANTIGEN; LEUKOCYTE ANTIGEN;

ADULT; ANTIGEN DETECTION; ANTIGEN FUNCTION; ARTICLE; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; CORRELATION ANALYSIS; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; TRIACYLGLYCEROL BLOOD LEVEL; AGED; BLOOD; CASE CONTROL STUDY; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; METABOLISM; MIDDLE AGED; PHYSIOLOGY;

ADULT; AGED; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN RESISTANCE; INTERLEUKIN-6; MACROPHAGES; MALE; MIDDLE AGED; RECEPTORS, CELL SURFACE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84865436485     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-012-2533-1     Document Type: Article

References (31)

1. Chen J, Wildman RP, Hamm LL et al (2004) Association between inflammation and insulin resistance in U. S. nondiabetic adults: results from the Third National Health and Nutrition Examination Survey. Diabetes Care 27:2960-2965 (Pubitemid 39565066)
2. Kershaw EE, Flier JS (2004) Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 89:2548-2556 (Pubitemid 38766330)
3. Zeyda M, Stulnig TM (2007) Adipose tissue macrophages. Immunol Lett 112:61-67 (Pubitemid 47379852)
4. Plomgaard P, Bouzakri K, Krogh-Madsen R, Mittendorfer B, Zierath JR, Pedersen BK (2005) Tumor necrosis factor-alpha induces skeletal muscle insulin resistance in healthy human subjects via inhibition of Akt substrate 160 phosphorylation. Diabetes 54:2939-2945 (Pubitemid 41401090)
5. Rieusset J, Bouzakri K, Chevillotte E et al (2004) Suppressor of cytokine signaling 3 expression and insulin resistance in skeletal muscle of obese and type 2 diabetic patients. Diabetes 53:2232-2241 (Pubitemid 39145576)
6. Popa C, Netea MG, van Riel PL, van der Meer JW, Stalenhoef AF (2007) The role of TNF-alpha in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk. J Lipid Res 48:751-762
7. Camussi G, Albano E, Tetta C, Bussolino F (1991) The molecular action of tumor necrosis factor-alpha. Eur J Biochem 202:3-14
8. Black RA, Rauch CT, Kozlosky CJ et al (1997) A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 385:729-733 (Pubitemid 27098094)
9. Etzerodt A, Maniecki MB, Moller K, Moller HJ, Moestrup SK (2010) Tumor necrosis factor alpha-converting enzyme (TACE/ADAM17) mediates ectodomain shedding of the scavenger receptor CD163. J Leukoc Biol 88:1201-1205
10. Axelsson J, Moller HJ, Witasp A et al (2006) Changes in fat mass correlate with changes in soluble sCD163, a marker of mature macrophages, in patients with CKD. Am J Kidney Dis 48:916-925 (Pubitemid 44895371)
11. Zanni MV, Burdo TH, Makimura H, Williams KC, Grinspoon SK (2011) Relationship between monocyte/macrophage activation marker soluble CD163 and insulin resistance in obese and normal-weight subjects. Clin Endocrinol (Oxf). doi:10.1111/j.1365-2265.2011.04284.x
12. Levy AP, Purushothaman KR, Levy NS et al (2007) Downregulation of the hemoglobin scavenger receptor in individuals with diabetes and the Hp 2-2 genotype: implications for the response to intraplaque hemorrhage and plaque vulnerability. Circ Res 101:106-110 (Pubitemid 47094629)
13. Moller HJ, Frikke-Schmidt R, Moestrup SK, Nordestgaard BG, Tybjaerg-Hansen A (2011) Serum soluble CD163 predicts risk of type 2 diabetes in the general population. Clin Chem 57:291-297
14. Krabbe KS, Nielsen AR, Krogh-Madsen R et al (2007) Brainderived neurotrophic factor (BDNF) and type 2 diabetes. Diabetologia 50:431-438
15. Alberti KG, Zimmet PZ (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15:539-553 (Pubitemid 28319935)
16. Moller HJ, Hald K, Moestrup SK (2002) Characterization of an enzyme-linked immunosorbent assay for soluble CD163. Scand J Clin Lab Invest 62:293-299
17. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-419 (Pubitemid 15018832)
18. Levy JC, Matthews DR, Hermans MP (1998) Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care 21:2191-2192 (Pubitemid 28549174)
19. UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853
20. Ginsberg HN, Zhang YL, Hernandez-Ono A (2006) Metabolic syndrome: focus on dyslipidemia. Obesity (Silver Spring) 14(Suppl 1):41S-49S
21. Moller HJ, Petersen PH, Rejnmark L, Moestrup SK (2003) Biological variation of soluble CD163. Scand J Clin Lab Invest 63:15-21 (Pubitemid 36461145)
22. Morris DL, Singer K, Lumeng CN (2011) Adipose tissue macrophages: phenotypic plasticity and diversity in lean and obese states. Curr Opin Clin Nutr Metab Care 14:341-346
23. Bourlier V, Zakaroff-Girard A, Miranville A et al (2008) Remodeling phenotype of human subcutaneous adipose tissue macrophages. Circulation 117:806-815 (Pubitemid 351640682)
24. Zeyda M, Farmer D, Todoric J et al (2007) Human adipose tissue macrophages are of an anti-inflammatory phenotype but capable of excessive pro-inflammatory mediator production. Int J Obes (Lond) 31:1420-1428 (Pubitemid 47339934)
25. Meshkani R, Adeli K (2009) Hepatic insulin resistance, metabolic syndrome and cardiovascular disease. Clin Biochem 42:1331-1346
26. Oliver JC, Bland LA, Oettinger CW et al (1993) Cytokine kinetics in an in vitro whole blood model following an endotoxin challenge. Lymphokine Cytokine Res 12:115-120 (Pubitemid 23141784)
27. Shakeri-Manesch S, Zeyda M, Huber J, Ludvik B, Prager G, Stulnig TM (2009) Diminished upregulation of visceral adipose heme oxygenase-1 correlates with waist-to-hip ratio and insulin resistance. Int J Obes (Lond) 33:1257-1264
28. Sporrer D, Weber M, Wanninger J et al (2009) Adiponectin downregulates CD163 whose cellular and soluble forms are elevated in obesity. Eur J Clin Invest 39:671-679
29. Alberti KG, Eckel RH, Grundy SM et al (2009) Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120:1640-1645
30. Goldfine AB, Gerwien RW, Kolberg JA et al (2011) Biomarkers in fasting serum to estimate glucose tolerance, insulin sensitivity, and insulin secretion. Clin Chem 57:326-337
31. Inoue N (2006) Vascular C-reactive protein in the pathogenesis of coronary artery disease: role of vascular inflammation and oxidative stress. Cardiovasc Hematol Disord Drug Targets 6:227-231 (Pubitemid 44890585)